NVAX - Novavax, Inc.
After hours:
Chart Events
Double Moving Average Crossover
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 7.43 |
| Open | 7.43 |
| Bid | 0.00 x 3200 |
| Ask | 0.00 x 800 |
| Day's Range | 7.40 - 8.13 |
| 52 Week Range | 5.61 - 76.77 |
| Volume | |
| Avg. Volume | 6,014,177 |
| Market Cap | 694.756M |
| Beta (5Y Monthly) | 1.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -14.93 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.00 |
Fair Value
Related Research
ZacksEMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval
Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.
The Wall Street JournalNext Covid Boosters to Target New Strain
Health authorities and vaccine makers are moving toward targeting the next shot on a form of the XBB strain that is now circulating widely in the U.S.
Investor's Business DailyIs Novavax Stock A Buy Or A Sell As Shares Stage A Comeback On A Cost-Cutting Plan?
Novavax stock is on the rise after announcing a cost-cutting plan and bullish sales guidance. Is NVAX stock a buy or a sell today?
PR NewswireNovavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that Nuvaxovid™ (NVX-CoV2373) has been recommended for full Marketing Authorization (MA) for use as a primary series in individuals aged 12 and older and as a booster in individuals aged 18 and older for the prevention of COVID-19 in the European Union (EU) following a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the Europea
Motley FoolWall Street Expects These Stocks to Soar 175% and 545%. Should You Buy?
Wall Street has high hopes for certain stocks over the coming 12 months. Two of them are biotech companies that took center stage during earlier days of the pandemic. Both companies raced to bring a coronavirus vaccine to market.
InvestorPlaceThe 3 Best Stocks to Short in May 2023
One of the places to find the best stocks to short are by viewing the Short Interest tables of major financial publications like MarketWatch and the Wall Street Journal. It’s there you find the heavily shorted stocks in the markets. As Investopedia states, “Short interest is the number of shares that have been sold short and remain outstanding.” When the short interest rises for an individual stock, it could indicate that investors are souring on that stock. The inverse applies when the short in
- InvestorPlace
Artificial Intelligence Engine Predicts NVAX Stock to Gain 7% by June 15
The world’s foremost artificial intelligence stock trading algorithm, An-E, predicts that Novavax (NASDAQ:NVAX) stock will gain 7% by June 15. An-E (pronounced Annie) has made this kind of prediction before. Back in December, Wall Street was bullish on Johnson & Johnson (NYSE:JNJ). Analysts were convinced JNJ could only go up… but An-E knew better. The algorithm said that JNJ stock was headed down 10% over one month… and JNJ stock fell that exact amount. Wall Street was shocked… but An-E saw it
Motley FoolThinking of Buying Novavax Stock? 3 Numbers You Should Look at First
There's been lots of excitement surrounding Novavax (NASDAQ: NVAX). Cash burn is a big concern for a company such as Novavax, which is likely to see its revenue decline as demand for its COVID-19 vaccine dwindles. As of the end of March, the company had $625 million in cash and cash equivalents on the books -- down by more than half from more than $1.3 billion it reported at the end of 2022.
Motley FoolWall Street Expects These Unique Stocks to Skyrocket 314% to 943%
Select analysts believe three former high-flying stocks can make their shareholders significantly richer.
Motley FoolUp 40% in 1 Day, Is Novavax Stock a Buy Now?
On May 9, Novavax (NASDAQ: NVAX) shareholders got a much-needed reprieve from the stock's downward trajectory over the last year. Novavax's decline is a regrettable one. Its coronavirus vaccine candidate ran into regulatory issues during clinical development, and arrived on the market much later than those of competitors like Pfizer and Moderna.
Motley FoolCovid Vaccine Producer Says Government Should Stick to Their Promises
The World Health Organization recently announced covid is no longer a global emergency. Hooray! That is unless you're Novavax, the biotech outfit...
Simply Wall St.This Just In: Analysts Are Boosting Their Novavax, Inc. (NASDAQ:NVAX) Outlook for This Year
Shareholders in Novavax, Inc. ( NASDAQ:NVAX ) may be thrilled to learn that the analysts have just delivered a major...
Motley FoolNovavax's New CEO Leads Vaccine Trial Success, and Big Layoffs Too
Novavax (NASDAQ: NVAX) investors have been on edge ever since the company fell behind in the coronavirus vaccine race. To make matters worse, earlier this year, Novavax even questioned its ability to continue operations. Jacobs revealed details about his strategy to cut costs, manage cash flow, and match Novavax's size to the demand for its only product: the coronavirus vaccine.
- PR Newswire
Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Singapore Health Sciences Authority (HSA) has granted extended interim authorization and the Ministry of Health has included Nuvaxovid™ (NVX-CoV2373) into the National Vaccination Programme as a non-mRNA option for adolescents aged 12 through 17 for active immunization to prevent COVID.
Motley FoolIs the Worst Over for Novavax?
In the early days of the COVID-19 pandemic, Novavax (NASDAQ: NVAX) took center stage. The biotech company became one of the first to enter clinical trials with a coronavirus vaccine candidate. Novavax's vaccine launched a year after those of the company's rivals, meaning Novavax missed out on the biggest revenue opportunity.
ZacksNovavax (NVAX) Q1 Earnings Lag, Stock Up 28% on Upbeat '23 View
Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.
- Zacks
Top Stock Picks for Week of May 8, 2023
A Biotech Company Developing Vaccines and a Restaurant Stock with Earnings Growth.
Yahoo Finance VideoNovavax stock surges amid earnings miss, 25% workforce reduction announcement
Yahoo Finance health care reporter Anjalee Khemlani details Novavax's latest earnings report.
Investor's Business DailyNovavax Rockets 28% On Upbeat Sales View, Cuts Workforce By A Quarter
Novavax an offered upbeat sales view Tuesday and announced a 25% reduction in its workforce to help cut costs — and NVAX stock rocketed.
Barrons.comBiotech Layoffs Keep Coming as Funding Squeeze Drags On
A flurry of good news lifted the SPDR S&P Biotech ETF last week, but more news about job cuts emerged on Monday and Tuesday.
Yahoo FinanceNovavax CEO: 'One thing we did was change the relationship with the FDA'
Novavax is under pressure to advance its pipeline as the public health emergency ends and Covid demand wanes.
TheStreet.comNovavax Rallies and More Gains May Lie Ahead
Novavax rallied Tuesday on the heels of their Q1 2023 results and positive trial data. A large layoff announcement may also be helping the stock rally. The On-Balance-Volume (OBV) line looks like it has bottomed in March and April signaling a shift towards more aggressive buying.
BenzingaNovavax Eases Uncertainty, Announces Job Cuts, Encouraging Data From COVID/Flu Combo Shot
Novavax Inc (NASDAQ: NVAX) announced a global restructuring and cost reduction plan, expected to reduce annual combined 2024 R&D and SG&A expenses by approximately 40% to 50% versus 2022. The streamlining includes a workforce reduction of approximately 25%. Last month, Novavax's newly appointed CEO, John Jacobs, said the company would cut about $50 million in costs in Q1 of 2023 and plans further cuts. For the first quarter, Novavax reported $81 million in total revenue — compared to $704 millio
Barrons.comNovavax Plans to Cut 25% of Staff. Here’s Why the Stock Is Soaring.
The Covid-19 vaccine manufacturer is aiming to sharply reduce costs as it hopes to bring new shots to the market.
Yahoo Finance VideoNovavax shares skyrocket after company reveals job cuts
Yahoo Finance Live’s Julie Hyman reports that Novavax will reduce its global workforce by 25%.